Ariad Pharmaceuticals Inc fka ARIA

[LUMA14]

Third-Generation TKI Most Promising Option for Ph+ ALL

link to article

...
Jabbour reviewed the history of TKI use in Ph+ ALL and the emerging promise of first-line ponatinib in combination with chemotherapy.
...
“It is possible that we may be able to eventually stop using chemotherapy,” he said. “Blinatumomab has shown that some patients respond very well. Therefore, our next step is to combine blinatumomab with ponatinib to improve CMR, minimize relapse concern, get rid of chemotherapy, and cure these patients. I think the outlook is very bright in PH+ ALL.”
...